Theory Paper IIDrNB Cardiology – Theory Notes

BRUGADA SYNDROME

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IDEFINITION, GENETICS AND ECG CLASSIFICATION (ESC 2022 VA/SCD GUIDELINES)

  • Definition: Brugada Syndrome (BrS) is an inherited primary electrical channelopathy (8:1 male predominance; highest prevalence in South and Southeast Asia) predisposing to nocturnal or fever-triggered polymorphic Ventricular Tachycardia (pVT), Ventricular Fibrillation (VF), and Sudden Cardiac Death (SCD) in the absence of overt structural heart disease.
  • Genetic and Cellular Substrate: Loss-of-function pathogenic variants in SCN5A (encoding the alpha-subunit of the cardiac Nav1.5 sodium channel) are identified in 20 to 30 percent of probands (the only gene with definitive ClinGen monogenic causality, though polygenic risk scores strongly modulate penetrance), causing either a transmural Phase 1 repolarization gradient (unopposed epicardial Ito current -> Phase 2 re-entry) or delayed conduction and micro-fibrosis in the epicardial Right Ventricular Outflow Tract (RVOT) (depolarization hypothesis).
  • ECG Classification (Only the Type 1 Pattern is Diagnostic):
    • Type 1 (“Coved-Type”) Brugada ECG Pattern: J-point and coved ST-segment elevation of 2 mm (0.2 mV) or greater gradually descending into a negative (inverted) symmetric T wave with little or no isoelectric separation in at least one right precordial lead (V1 and/or V2) placed in the standard 4th, 3rd, or 2nd intercostal space (High Right Precordial Leads).
    • Type 2 (and Historical Type 3) (“Saddleback”) Pattern: J-point elevation >=2 mm with a saddleback ST-segment remaining >=1 mm (Type 2) or <1 mm (Type 3) above baseline and a positive or biphasic T wave. Not diagnostic of BrS unless converted to a Type 1 pattern during fever or a Sodium Channel Blocker Challenge (Ajmaline 1 mg/kg, Flecainide 2 mg/kg, or Procainamide 10 mg/kg IV).

IITHE SHANGHAI SCORING SYSTEM AND ESC 2022 DIAGNOSTIC CRITERIA

  • Why Scoring is Required: Because a drug-induced Type 1 ECG can occur in 2 to 4 percent of healthy individuals (false-positive provocation), the Shanghai Brugada Score and 2022 ESC Guidelines require clinical, family, or genetic corroboration when the Type 1 pattern is not spontaneous:
  • Spontaneous Type 1 ECG (3.5 points): Diagnostic of BrS on its own in patients with no other heart disease (Class I in ESC 2022).
  • Fever-Induced (3.0 points) or Drug-Induced (2.0 points) Type 1 ECG: Requires additional clinical features (survived cardiac arrest/documented VF [3.0 pts], suspected arrhythmic syncope [2.0 pts], nocturnal agonal respiration [2.0 pts], or definite family history of BrS [2.0 pts]) to reach a Probable/Definite Shanghai Score of >= 3.5 points (Class I in ESC 2022 if survivor of cardiac arrest; Class IIa if accompanied by arrhythmic syncope or family history).
Shanghai Score Category Specific Diagnostic Criterion (Select Highest Single Item per Category) Points Awarded
I. ECG (12-Lead / Ambulatory) Spontaneous Type 1 Brugada ECG at nominal or high (2nd/3rd ICS) leads 3.5 points
Fever-induced Type 1 Brugada ECG 3.0 points
Sodium-channel blocker-induced Type 1 Brugada ECG 2.0 points
II. Clinical History Unexplained cardiac arrest or documented VF / polymorphic VT 3.0 points
Nocturnal agonal respirations 2.0 points
Suspected arrhythmic syncope 2.0 points
III. Family History First- or second-degree relative with definite BrS (unexplained SCD <45 yr with negative autopsy scores only 0.5) 2.0 points
IV. Genetic Test Result Pathogenic mutation in a BrS susceptibility gene (SCN5A) 0.5 points
Diagnostic Threshold >= 3.5 Points = Probable/Definite BrS; 2.0–3.0 Points = Possible BrS Requires >=1 ECG finding

IIILIFESTYLE, PHARMACOLOGICAL AND DEVICE MANAGEMENT (ESC 2022 GUIDELINES)

  • Mandatory Lifestyle Measures in All BrS Patients (Class I):
    • Immediate Aggressive Treatment of Fever: High body temperature prematurely inactivates mutant Nav1.5 channels; any fever must be treated immediately with antipyretics (Paracetamol/Acetaminophen), and febrile patients with a Type 1 ECG require hospital telemetry monitoring.
    • Strict Avoidance of Offending Drugs and Triggers: Avoid all Class I antiarrhythmics (Flecainide, Propafenone, Ajmaline, Procainamide), tricyclic antidepressants, lithium, high-dose propofol/bupivacaine (complete list at brugadadrugs.org), cocaine, cannabis, and excessive alcohol intake or large heavy meals (which heighten vagal tone).
    • Implantable Cardioverter-Defibrillator (ICD) Indications:
    • Secondary Prevention (Class I): Mandatory in survivors of aborted cardiac arrest or patients with documented spontaneous sustained VT/VF (Subcutaneous ICD [S-ICD] is an attractive option in young BrS patients without pacing needs or monomorphic VT).
    • Primary Prevention in Syncope (Class IIa): Recommended in patients with a spontaneous Type 1 ECG and a history of arrhythmic syncope. (An Implantable Loop Recorder [ILR] is Class IIa when syncope is of uncertain/vasovagal origin.)
    • Asymptomatic Patients: Routine ICD is not recommended in asymptomatic drug-induced BrS; in asymptomatic patients with a spontaneous Type 1 ECG, Programmed Electrical Stimulation (PES) up to two extrastimuli may be considered (Class IIb) for risk stratification.
    • Pharmacotherapy:
    • Quinidine (Class IIa): Blocks the outward potassium current (Ito), restoring the epicardial action potential dome. Indicated in patients with recurrent ICD shocks, electrical storm, or when an ICD is contraindicated or refused.
    • Intravenous Isoproterenol (Class IIa for Electrical Storm): Continuous infusion (1 to 2 mcg/min) augments inward L-type calcium current (ICa-L) and increases heart rate, acutely abolishing ST-segment elevation and VF electrical storm.

IVEPICARDIAL RVOT SUBSTRATE ABLATION AND THE INDIAN CONTEXT

  • Epicardial RVOT Substrate Catheter Ablation (Nademanee / Pappone Technique — ESC 2022 Class IIa):
    • Mechanism: High-density 3D mapping identifies low-voltage, prolonged, fractionated late potentials localized on the anterior epicardial surface of the RVOT (unmasked completely by IV ajmaline/flecainide or warm saline infusion into the pericardium).
    • Evidence (BRAVO Registry, Circulation 2023): Percutaneous epicardial radiofrequency ablation of all abnormal RVOT substrate electrograms aims to normalize the Type 1 Brugada ECG (normalization independently predicted a VF-free outcome) and achieved VF freedom in 81 percent after one procedure and 96 percent after repeat procedures (n = 159, mean follow-up ~4 years); ablation carries a Class IIa recommendation in the 2022 ESC Guidelines for patients with recurrent appropriate ICD shocks or electrical storm refractory to/intolerant of Quinidine.
    • Practical Considerations in the Indian Context:
    • Tropical Febrile Infections (Dengue, Malaria, Enteric Fever, Viral Pyrexia): In India, acute tropical febrile illnesses are a common trigger unmasking a Fever-Induced Type 1 Brugada ECG and precipitating VF arrest; immediate antipyretics, correction of hypokalemia, and telemetry monitoring until defervescence are mandatory.
    • Pharmacological Alternatives When Quinidine is Unavailable: Because oral Quinidine has limited commercial availability in India, oral Cilostazol (100 mg BD; a PDE-3 inhibitor that increases ICa-L and heart rate) or Theophylline is occasionally used as an empirical bridge alongside Epicardial RVOT Catheter Ablation in tertiary Indian EP centers for patients with recurrent ICD shocks.

Key references

  • Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al.: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, European Heart Journal, 2022.
  • Antzelevitch C, Yan GX, Ackerman MJ, et al.: J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge (Shanghai Score), Heart Rhythm / Europace, 2016.
  • Nademanee K, Chung FP, Sacher F, et al. (BRAVO Registry Investigators): Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry), Circulation, 2023.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.